SHPH 1.32 Shuttle Pharmaceuticals Holdings, Inc.
| Range: | 1.03-4.96 | Vol Avg: | 550370 | Last Div: | 0 | Changes: | -0.02 |
| Beta: | 1.02 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Aug 31 2022 | Empoloyees: | 8 | ||
| CUSIP: | 825693203 | CIK: | 0001757499 | ISIN: | US8256932034 | Country: | US |
| CEO: | Dr. Anatoly Dritschilo M.D. | Website: | https://www.shuttlepharma.com | ||||
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow